Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
Élisa Gobbini(Institut Curie), Silvia Novello(University of Turin), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Massimo Di Maïo(University of Siena), Claudia Bareggi(University of Milan), Olga Martelli(Agostino Gemelli University Polyclinic), Vieri Scotti(University of Florence), Paola Bordi, Sara Pilotto(University of Verona), Domenico Galetta(Istituto Tumori Bari), Rita Chiari(Azienda Ospedaliera di Perugia), Gloria Borra, Emilio Bria(Università Cattolica del Sacro Cuore), Antônio Rossi(Università Campus Bio-Medico), Paolo Graziano(Pathological Society), Vanesa Gregorc(IRCCS Ospedale San Raffaele), Fabiana Letizia Cecere, Evaristo Maiello(Casa Sollievo della Sofferenza), Fabrizio Tabbò(Ospedale San Pietro Fatebenefratelli), Giulio Rossi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Laura Ghilardi(Ospedale Papa Giovanni XXIII), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), P. Pizzutillo(Istituto Tumori Bari), Marcello Tiseo(University of Parma), Clelia Casartelli(Ospedale Valduce), P. Rizzo(Institute for Coastal Marine Environment), Alessandro Del Conte(University of Catania), Concetta Sergi(Ospedale Garibaldi), Giorgia Osman, Federico Cappuzzo(Ospedale di Livorno)
Cited by 5
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k